FDA Grants Toripalimab Fast Track Designation for mucosal melanoma

Toripalimab is a PD-1 monoclonal antibody which will be investigated in the Phase III Combination RCT in combination with axitinib versus pembrolizumab as a first-line treatment in patients with unresectable, locally advanced or metastatic mucosal melanoma.

Source:

Biospace Inc.